Cognitive recovery following immune effector cell-associated neurotoxicity syndrome in the first 6 months after chimeric antigen receptor T-cell therapy
Patients who develop ICANS demonstrate no strong evidence of significant cognitive decline in the six months post-CAR-T therapy. Our data are reassuring, revealing that ICANS-related cognitive impairment resolves sometime in the first three months post-CAR-T therapy in most cases.
Authors
- Miriam Wronski (ORCID: https://orcid.org/0000-0003-4888-7707)
- Constantine S. Tam
- Charles Benjamin Malpas (ORCID: https://orcid.org/0000-0003-0534-3718)
- Harshal Nandurkar (ORCID: https://orcid.org/0000-0002-8767-116X)
- Robb Wesselingh (ORCID: https://orcid.org/0000-0002-5898-3287)
- Daniel J. Pearce (ORCID: https://orcid.org/0000-0002-0223-3778)
- Elizabeth Cole
- Mastura Monif (ORCID: https://orcid.org/0000-0001-6404-9768)
- Christina Kazzi (ORCID: https://orcid.org/0000-0001-6737-5489)
- Cassandra Abbott
- Nabil Seery (ORCID: https://orcid.org/0000-0001-6446-868X)
- Tracie Tan
- Rubina Alpitsis
- Tiffany Rushen
- Andrew Spencer
- Michael Westworth
- Lauren Melitsis
- Shafqat Inam
- Ty Simpson
- Sriyani Parsons
- Sarah P Griffith
- Terence J. O’Brien
- Helmut Butzkueven
- Shu Min Wong
- Jian Kun Li
- Shaun Fleming
- Katherine Y Ko
- Anneke Van Der Walt
Institutions
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- The Alfred Hospital (AU)
- Monash Health (AU)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Transplantation and Cellular Therapy
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.jtct.2026.03.030
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00